(The Hill) — The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices.  According to senior administration officials, the two manufacturers have agreed to sell their injectable GLP-1 products, Novo Nordisk's Wegovy and Lilly’s Zepbound, for a [...]

See Full Page